<DOC>
	<DOC>NCT01758380</DOC>
	<brief_summary>To evaluate vildagliptin as compared to gliclazide, given in combination with metformin in Muslim patients with type 2 diabetes fasting during Ramadan.</brief_summary>
	<brief_title>Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>Confirmed Type 2 Diabetes diagnosis Plan to fast during Ramadan Treated with a combination of metformin and an Sulfonylurea (SU) for at least 12 weeks and HbA1c ≤8.5% at Visit 1 Taking a sulfonylurea treatment for less than 3 years prior to Visit 1 Body mass index (BMI) ≥22 and ≤45 kg/m2 at Visit 1 Pregnant or nursing (lactating) women History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes. Patients who are taking any other antidiabetes drug (oral or injection) other than metformin and an SU component. Inability to comply with the study procedures or medications. "Other protocoldefined inclusion/exclusion criteria may apply"</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Ramadan</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>Hypoglycemia</keyword>
</DOC>